FORWARD-LOOKING STATEMENTS Certain statements in this Annual Report contain forward-looking statements regarding the Company’s business and the technical and commercial potential of its technologies and products in development. Any statement describing the Company’s goals, expectations, intentions, or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of discovering, developing, and commercialising medical devices that can be proven to be safe and effective for use in humans, and in the endeavour of building a business around such products and services. INOVIQ undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Actual results could differ materially from those discussed in this Annual Report. As a result, readers of this report are cautioned not to rely on forward-looking statements. ROUNDING No rounding has been applied to the amounts contained in the financial report under the option available to the Company under ASIC Corporations (Rounding in Financial/Director’s report) instrument 2016/191. The Company is an entity to which the legislative instrument applies. SIGNIFICANT EVENTS AFTER THE BALANCE DATE The following announcement was made via the ASX announcement platform since the end of the reporting period: – On 5 July 2024, the Company announced the completion of the Share Purchase Plan (SPP) component of the capital raise announced on 12 June 2024. The SPP raised $2.379m (gross) post 30 June 2024 and issued 4,758,000 shares and 2,378,914 listed options on 9 July 2024; – 6,749,999 listed options attaching to the June 2024 placement were also issued on 9 July 2024; and – On 20 August 2024, the Company announced that it had further validated its NEURO-NET technology for isolation of brain-derived exosomes in Parkinsons’ Disease. At the date of this report, other than that outlined above, there have been no matters or circumstances that have arisen since the end of the period which significantly, or may significantly effect: – The Group’s operations in future years; – The results of those operations in future years; or – The Group’s state of affairs in future years. SIGNIFICANT CHANGES IN THE STATE OF AFFAIRS Other than those outlined in this report there were no other significant changes in the state of affairs of the Company during the period. FINANCIAL POSITION The net assets of the Group at 30 June 2024 totalled $19,986,328 (2023: $19,615,397). Total assets at 30 June 2024 totalled $21,705,703 (2023: $21,508,818). The Group had cash and cash equivalents of $9,233,192 at 30 June 2024 (2023: $7,812,511). DIVIDENDS No dividend has been declared, provided for or paid in respect of the year ended 30 June 2024 or 30 June 2023. INDEMNIFICATION AND INSURANCE OF DIRECTORS AND OFFICERS The Company has insurance in place to indemnify directors of the Company against liability incurred to a third party (not being the Company or a related party) that may arise from their position as directors or officers of the Company. In accordance with subsection 300(9) of the Corporations Act 2001, further details have not been disclosed due to confidentiality provisions of the insurance contracts. INDEMNIFICATION OF AUDITORS The Group has not, during or since the end of the financial year, indemnified or agreed to indemnify the auditor of the Group or any related entity against a liability incurred by the auditor. During the financial year, the Group has not paid a premium in respect of a contract to insure the auditor of the Group or any related entity. INTERESTS IN CONTRACTS OR PROPOSED CONTRACTS WITH THE COMPANY During the financial year, no director has had any interest in a contract or proposed contract with the Company being an interest the nature of which has been declared by the director in accordance with Section 300(11)(d) of the Corporations Act 2001 except for the contracts of the executive and non-executive director which are disclosed in the remuneration report. Directors’ Report continued 24 INOVIQ Limited
RkJQdWJsaXNoZXIy MjE2NDg3